CIK 0001124105
- Accelerated filer
- Smaller reporting company
GYRE THERAPEUTICS, INC.
Sign in to watch- Ticker
- GYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 562020050
- Phone
- +1 858-284-0115
- Business address
- 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
- Former names
- CATALYST BIOSCIENCES, INC., TARGACEPT INC
- 4 Open-market buy Chief Scientific Officer bought 3,250 shares at $0.46 ($1,495)
- 4 Grant or award Director acquired 12,308 shares (grant or award)
- 4 Grant or award Director acquired 12,855 shares (grant or award)
- 4 Grant or award Director acquired 7,521 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 2,980 shares (grant or award)
- 4 Grant or award Director acquired 2,858 shares (grant or award)
- 4 Grant or award Director acquired 5,839 shares (grant or award)
- 4 Grant or award Director acquired 1,824 shares (grant or award)
- 4 Grant or award Director acquired 3,588 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy President & CEO bought 867 shares at $3.62 ($3,139)
- 4 Open-market buy Chief Medical Officer bought 639 shares at $3.62 ($2,313)
- 4 Open-market buy Chief Scientific Officer bought 1,163 shares at $3.62 ($4,210)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 1,414 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 2,713 shares (grant or award)
- 4 Grant or award Director acquired 5,542 shares (grant or award)
Page 8 of 37 · 739 filings